Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
Possible immunogenicity of the Cas9 protein raises concerns about therapeutic applications. Here the authors identify pre-existing CD8+T-cell immunity in healthy individuals and in response modify Cas9 to remove the immunodominant epitopes.
Main Authors: | Shayesteh R. Ferdosi, Radwa Ewaisha, Farzaneh Moghadam, Sri Krishna, Jin G. Park, Mo R. Ebrahimkhani, Samira Kiani, Karen S. Anderson |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-09693-x |
Similar Items
-
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
by: Radwa Ewaisha, et al.
Published: (2023-02-01) -
Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas
by: Farzadfard, Fahim, et al.
Published: (2013) -
A Multifunctional and Highly Adaptable Reporter System for CRISPR/Cas Editing
by: Jochen M. Wettengel, et al.
Published: (2023-05-01) -
Insights into the inhibition of type I-F CRISPR-Cas system by a multifunctional anti-CRISPR protein AcrIF24
by: Lingguang Yang, et al.
Published: (2022-04-01) -
Generation of epitope tag knock-in mice with CRISPR-Cas9 to study the function of endogenous proteins
by: Zhao Zhang
Published: (2023-09-01)